Final answer:
Exelixis would file a Supplemental New Drug Application (sNDA) with the FDA to market cabozantinib for liver cancer after its approval for kidney cancer.
Step-by-step explanation:
To market cabozantinib for liver cancer after it has already been approved for kidney cancer, Exelixis would need to file a Supplemental New Drug Application (sNDA) with the Food and Drug Administration (FDA). An sNDA is submitted for an existing approved drug when there is a proposed change to the labeling, formulation, or dosage, or if there is a new indication for use.
Since cabozantinib is effective for a type of liver cancer and has already been approved for kidney cancer, this application is appropriate to extend its marketing to include treatment for liver cancer.